Active Studies

  •  A Study of Zatolmilast in Male Adults (Aged 9 to 45) With Fragile X Syndrome – This study is looking at an investigational drug, Zatolmilast, as possible treatment for Fragile X Syndrome. The main goals of the study are to look at how well the study drug works and if it is safe. The study is now closed to enrollment of males aged 9-45 years old. These participants have since rolled over to the open-label study where they are looking at long term use of the study drug.  

    For more info on our Phase 3 Clinical Trial

  • Gabapentin Trial with MRI: Research study for adolescents with an Autism Spectrum Disorder (ASD) – A Magnetic Resonance Imaging clinical trial with gabapentin to test how this drug affects neurotransmitter levels. We are also testing whether this drug leads to clinically measurable improvement in core social cognition problems in adolescents ages 13 to 17 with ASD. Please see our Gabapentin Trial with MRI study brochure
  • UMass Baby Brain Study – This study uses functional magnetic resonance imaging (fMRI) and functional near-infrared spectroscopy (fNIRS) to examine how a baby’s social brain develops in the first year of life. We are particularly interested in understanding how the natural hormones of the brain and early social environment influence long-term developmental outcomes, with the goal of discovering innovative strategies for diagnosis, prevention, and treatment in at-risk babies and families. (PI: Kim)

    Please see our BabyBrain_Flyer.pdf
  • Neonatal Biomarkers StudyNeonatal Biomarkers in Extremely Preterm Babies Predict Childhood Brain Disorders: The Elgan-3 Study (Extremely low gestational age newborns) 

    With support from the National Institutes of Health (NIH) the Extremely Low Gestational Age Newborn Study completed its third wave of study visits (age 15 year) and begins the fourth wave, as participants reach 17 years of age.

    The NIH selected ELGAN, along with similar studies in the United States, to join in a study of about 50,000 children to learn how the Environment influences Child Health Outcomes (ECHO). You can read more about ECHO at 

    ELGAN researchers have followed over one thousand children born at least 3 months early between 2002 and 2004 at 14 different hospitals in five states. We assessed these premature babies at birth and again when they were two and ten years old. In the first few weeks after birth, when the babies had routine blood tests, we saved a drop or two for later testing. Through analyzing these saved blood samples, we learned that children who had signs of sustained inflammation in their blood were more likely to have development problems when they were 2 and 10 years old.

    See our study: 

     Other ongoing research studies at the Shriver Center    .